Khushalani N I, Bakri F G, Wentling D, Brown K, Mohr A, Anderson B, Keesler C, Ball D, Bernstein Z P, Bernstein S H, Czuczman M S, Segal B H, McCarthy P L
Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Bone Marrow Transplant. 2001 May;27(10):1071-3. doi: 10.1038/sj.bmt.1703046.
Respiratory syncytial virus (RSV) infection is an important cause of respiratory mortality in immunosuppressed patients, including bone marrow transplant (BMT) recipients. The presence of lower respiratory tract infection and infection in the pre-engraftment phase of BMT is believed to confer a poor prognosis. Three patients who underwent allogeneic BMT at our institution developed RSV pneumonia over 1 year post BMT, with the underlying disease in remission. All three were hypoxic with extensive pulmonary disease at presentation. Treatment consisted of aerosolized ribavirin and intravenous immune globulin with successful clearing of viral shedding and excellent clinical outcomes. RSV infection is probably less severe in the late post-BMT period, but needs to be considered early in the differential diagnosis of pulmonary infiltrates in this patient population.
呼吸道合胞病毒(RSV)感染是免疫抑制患者(包括骨髓移植(BMT)受者)呼吸相关死亡的重要原因。在下呼吸道感染以及BMT植入前阶段出现感染被认为预后不良。在我们机构接受异基因BMT的3例患者在BMT后1年以上发生了RSV肺炎,基础疾病处于缓解期。所有3例患者就诊时均有缺氧及广泛肺部病变。治疗包括雾化利巴韦林和静脉注射免疫球蛋白,病毒排出成功清除,临床结局良好。RSV感染在BMT后期可能病情较轻,但在该患者群体肺部浸润的鉴别诊断中需尽早考虑。